Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CCR3 blockade as a new therapy for asthma.

C P Bertrand1, P D Ponath

  • 1Inflammatory Diseases Unit, Roche Bioscience, Palo Alto, CA 94304, USA. claude.bertrand@wl.com

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary

Chemokine receptor CCR3 is crucial for eosinophil and T-cell recruitment in asthma. Blocking CCR3 effectively halts eosinophil responses, offering a promising new therapeutic strategy for asthma treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma.

The European respiratory journal·2011
Same author

Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice.

The European respiratory journal·2006
Same author

Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS.

Expert opinion on investigational drugs·2005
Same author

Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2005
Same author

Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis.

Allergy·2002
Same author

CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease.

Gastroenterology·2001

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Cell Biology

Background:

  • Eosinophils and Th2 cells are key players in asthma pathogenesis.
  • Chemokines are implicated in selective leukocyte recruitment in atopic diseases.
  • Specific chemokines like RANTES, MCP-3, MCP-4, and eotaxins induce eosinophil chemotaxis and pro-inflammatory activities.

Purpose of the Study:

  • To investigate the role of chemokine receptor CCR3 in eosinophil and T-cell trafficking in asthma.
  • To determine if CCR3 is responsible for the chemokine selectivity profile observed in eosinophils.
  • To evaluate CCR3 blockade as a potential therapeutic strategy for asthma.

Main Methods:

  • In vitro ligand binding and chemotaxis assays using chemokines and eosinophils.
  • Cloning of the G-protein coupled-receptor (GPCR) CCR3 from eosinophils.
  • Experiments involving monoclonal antibody blockade of CCR3 on eosinophils.
  • Analysis of CCR3 expression on Th2 cells and T-cells in diseased tissue.

Main Results:

  • CCR3 demonstrated a chemokine selectivity profile identical to that of eosinophils.
  • Blocking CCR3 on eosinophils with a monoclonal antibody completely inhibited their responses to tested chemokines.
  • CCR3 was detected on in vitro derived Th2 cells and T-cells co-localizing with eosinophils in asthmatic tissue.

Conclusions:

  • CCR3 plays a central role in eosinophil trafficking.
  • CCR3 mediates the recruitment of Th2 cells into the airways, contributing to asthma pathogenesis.
  • CCR3 blockade represents a highly attractive and innovative therapeutic strategy for asthma.

Related Experiment Videos